About Hybio Pharmaceutical
Hybio Pharmaceutical is a company based in Shenzhen (China) founded in 1998. Hybio Pharmaceutical has raised $15 million across 1 funding round from investors including Shenzhen Capital Group. Hybio Pharmaceutical has completed 1 acquisition, including AMW Pharmaceuticals. Hybio Pharmaceutical operates in a competitive market with competitors including Enzene Biosciences, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others.
- Headquarter Shenzhen, China
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hybio Pharmaceutical Co., Ltd. Class A
-
Annual Revenue
$80.86 M (USD)40.95as on Dec 31, 2024
-
Net Profit
-$24.72 M (USD)64.89as on Dec 31, 2024
-
EBITDA
Not available
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series A
Mar 19, 2008
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hybio Pharmaceutical
Hybio Pharmaceutical is a publicly listed company on the SZSE with ticker symbol 300199 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Hybio Pharmaceutical
Hybio Pharmaceutical has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in March 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hybio Pharmaceutical
Hybio Pharmaceutical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Shenzhen Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital, equity investment, and fund management services in China.
|
Locked | Locked | Locked |
Investor details for Hybio Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hybio Pharmaceutical
Hybio Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AMW Pharmaceuticals.
Investment portfolio details for Hybio Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Transdermal drug delivery technologies are developed and manufactured for therapeutics.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Hybio Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Hybio Pharmaceutical
Detailed financials for Hybio Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hybio Pharmaceutical Comparisons
Peer comparison for Hybio Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hybio Pharmaceutical
Hybio Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products
|
|
| Locked | Locked | Locked |
Drug R&D services for cardiovascular and metabolic diseases are provided.
|
Detailed competitors of Hybio Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hybio Pharmaceutical
Complete news archive for Hybio Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hybio Pharmaceutical
Hybio Pharmaceutical was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Hybio Pharmaceutical is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Jiancheng Yuan is the current CEO of Hybio Pharmaceutical.
Hybio Pharmaceutical is a funded company, having raised a total of $15M across 1 funding round to date.
Annual revenue of Hybio Pharmaceutical is $80.86M as on Dec 31, 2024.
Hybio Pharmaceutical was founded in 1998 and is based in Shenzhen, China. Operations focus on the pharmaceutical sector, with a portfolio that includes Desmopressin acetate, Thymopentin, Somatostatin, and Terlipressin. Customers are served in the US, Canada, Italy, India, Germany, and Russia. Custom peptide synthesis services are offered through CROCDO models, alongside GMP-compliant CMO capabilities for peptide production.
Hybio Pharmaceutical's top competitors include Enzene Biosciences, PolyPeptide and AmbioPharm.
Yes, Hybio Pharmaceutical is publicly traded on SZSE under the ticker symbol 300199.
Hybio Pharmaceutical has made 1 acquisition, including AMW Pharmaceuticals.
Hybio Pharmaceutical has 1 investor. Key investors include Shenzhen Capital Group.
The ticker symbol of Hybio Pharmaceutical is 300199 on SZSE.